Researcher Profiles

Return to member profile

Karine A. Cohen-Solal, PhD

Publications since 2011

Boregowda, R. K. Medina, D. J. Markert, E. Bryan, M. A. Chen, W. Chen, S. Rabkin, A. Vido, M. J. Gunderson, S. I. Chekmareva, M. Foran, D. J. Lasfar, A. Goydos, J. S. Cohen-Solal, K. A. The transcription factor RUNX2 regulates receptor tyrosine kinase expression in melanoma. Oncotarget, In process, . (PMID: 27102439)

Lasfar, A. Zloza, A. Cohen-Solal, K. A. IFN-lambda therapy: current status and future perspectives. Drug Discov Today, In process, . (PMID: 26552337)

Nahta, R. Al-Mulla, F. Al-Temaimi, R. Amedei, A. Andrade-Vieira, R. Bay, S. G Brown, D. Calaf, G. M. Castellino, R. C. Cohen-Solal, K. A. Colacci, A. Cruickshanks, N. Dent, P. Di Fiore, R. Forte, S. Goldberg, G. S. Hamid, R. A. Krishnan, H. Laird, D. W. Lasfar, A. Marignani, P. A. Memeo, L. Mondello, C. Naus, C. C. Ponce-Cusi, R. Raju, J. Roy, D. Roy, R. P Ryan, E. Salem, H. K. Scovassi, A. I. Singh, N. Vaccari, M. Vento, R. Vondracek, J. Wade, M. Woodrick, J. Bisson, W. H. Mechanisms of environmental chemicals that enable the cancer hallmark of evasion of growth suppression. Carcinogenesis, 36 Suppl 1:S2-S18, . (PMID: 26106139)

Cohen-Solal, K. A. Boregowda, R. K. Lasfar, A. RUNX2 and the PI3K/AKT axis reciprocal activation as a driving force for tumor progression. Mol Cancer, 14:137, . (PMID: 26204939)

Lasfar, A. Cook, J. R. Cohen Solal, K. A. Reuhl, K. Kotenko, S. V. Langer, J. Laskin, D. L. Critical Role of the Endogenous IFN Ligand-Receptors in Type I and Type II IFNs Response. Immunology, 142:442-452, . (PMID: 24597649, PMCID: PMC4080960)

Boregowda, R. K. Olabisi, O. O. Abushahba, W. Jeong, B. S. Haenssen, K. K. Chen, W. Chekmareva, M. Lasfar, A. Foran, D. J. Goydos, J. S. Cohen-Solal, K. A. RUNX2 is overexpressed in melanoma cells and mediates their migration and invasion. Cancer Lett, 348:61-70, . (PMID: 24657655, PMCID: PMC4041161)

Wen, Y. Y. Li, J. Koo, J. Shin, S. S. Lin, Y. Jeong, B. S. Mehnert, J. M. Chen, S. Cohen-Solal, K. Goydos, J. S. Activation of the Glutamate Receptor GRM1 Enhances Angiogenic Signaling to Drive Melanoma Progression. Cancer Res, 74:2499-2509, . (PMID: 24491800, PMCID: PMC4008638)

Abushahba, W. Olabisi, O. O. Jeong, B. S. Boregowda, R. K. Wen, Y. Liu, F. Goydos, J. S. Lasfar, A. Cohen-Solal, K. A. Non-Canonical Smads Phosphorylation Induced by the Glutamate Release Inhibitor, Riluzole, through GSK3 Activation in Melanoma. PLoS One, 7:e47312, . (PMID: 23077590, PMCID: PMC3470581)

Cohen-Solal, K. A. Merrigan, K. T. Chan, J. L. Goydos, J. S. Chen, W. Foran, D. J. Liu, F. Lasfar, A. Reiss, M. Constitutive Smad linker phosphorylation in melanoma: a mechanism of resistance to transforming growth factor-beta-mediated growth inhibition. Pigment Cell Melanoma Res, 24:512-524, . (PMID: 21477078, PMCID: PMC3108265)

Lasfar, A. Abushahba, W. Balan, M. Cohen-Solal, K. A. Interferon lambda: a new sword in cancer immunotherapy. Clin Dev Immunol, 2011:349575, . (PMID: 22190970, PMCID: PMC3235441)